Search clinical trials for: High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)

Total 231 results

Vanderbilt-Ingram Cancer Center

Completed

Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients

Adult Stem Cell Hematopoetic Transplant

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age (QHD04)

Influenza

United States, Canada
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

Influenza

United States
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

Influenza | Myxovirus Infection

United States
Vanderbilt University
University of Pittsburgh; MCM Vaccines B.V.

Completed

Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients

Pediatric Solid Organ Transplant Patients

United States
Vanderbilt University

Completed

Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients

Pediatric Patients With Acute Lymphoblastic Leukemia

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults

Influenza

United States, Puerto Rico, Canada
Sanofi Pasteur, a Sanofi Company

Completed

A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age

Influenza

United States
Sanofi

Terminated

Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older

Influenza

United States, Puerto Rico
Seqirus
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older

Influenza

Belgium
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort (SLVP033)

Hepatitis A | Influenza | Healthy Adults | Typhoid

United States
Roswell Park Cancer Institute

Completed

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Kaiser Permanente
Seqirus

Recruiting

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

Influenza | Community-acquired Pneumonia | Cardiovascular Events

United States
Sanofi Pasteur, a Sanofi Company

Terminated

Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

Influenza Immunization

United States, Puerto Rico
University of Colorado, Denver
University of Alabama at Birmingham; All India Institute of Medical Sciences... and other collaborators

Completed

Influenza Immunization of Children in India

Influenza

India
Sanofi Pasteur, a Sanofi Company
Sanofi K.K.

Completed

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years

Influenza

Japan
Emory University
National Cancer Institute (NCI); Sanofi; National Institutes of Health (NIH)

Completed

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

Plasma Cell Neoplasm

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

Japan
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Influenza, Human

United States
Tor Biering-Sørensen
Sanofi; Statens Serum Institut

Recruiting

A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults (DANFLU-2)

Influenza

Denmark
Tor Biering-Sørensen
Sanofi Pasteur, a Sanofi Company

Completed

Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting (DANFLU-1)

Influenza

Denmark
US Department of Veterans Affairs
St. Louis University

Withdrawn

MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly (CCTA #0005)

Aged | Influenza Vaccines

United States
University of Pittsburgh
Sanofi Pasteur, a Sanofi Company

Completed

Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting

Influenza

United States
Inova Health Care Services

Completed

Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.

Influenza, Human | Transplantation Infection

United States
Saad Jamshed MD
Sanofi

Completed

Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy (IMMUNE)

Cancer | Influenza Viral Infections

United States
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Influenza Disease

Argentina, Australia, Chile, Philippines, South Africa
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza (FluMist)

Influenza

South Africa
MedImmune LLC

Completed

A Phase 2 Study to Evaluate Immune Responses of FluMist®

Influenza Vaccine

United States
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; National Heart, Lung, and Blood... and other collaborators

Completed

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED)

Myocardial Infarction | Heart Failure

United States, Canada, Puerto Rico
Wayne Sullender, M.D.
All India Institute of Medical Sciences, New Delhi; Centers for Disease Control...

Completed

Direct and Indirect Protection by Influenza Vaccine Given to Children in India

Influenza

India
Insight Therapeutics, LLC
Brown University; Case Western Reserve University; Seqirus

Completed

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

Influenza | Influenza-like Illness

United States
Stanford University
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)

MELAS Syndrome

United States
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents

Influenza

United States
Marshfield Clinic Research Foundation
Centers for Disease Control and Prevention

Completed

Open-Label Influenza Vaccine Evaluation (OLIVE)

Immune Response

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)

Influenza

Lithuania
National Institute of Allergy and Infectious Diseases...

Completed

Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma

Influenza

United States
Sinovac Biotech Co., Ltd

Recruiting

Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial

Hand, Foot and Mouth Disease | Herpangina

China
University Hospital, Ghent

Completed

Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults (IPV-004)

Poliomyelitis

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years

Influenza

Korea, Republic of
UMC Utrecht
Netherlands Organisation for Scientific Research

Completed

Prevention of Respiratory Infections and MAnagement Among Children (PRIMAKid)

Recurrent Upper and Lower Respiratory Tract Infections (RTIs)

Netherlands
National Institute of Allergy and Infectious Diseases...

Withdrawn

High Dose Influenza in Immunosuppressed Subjects

Influenza

United States
Butantan Institute
Fundação Butantan

Recruiting

Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .

Influenza, Human

Brazil
University of Rochester

Completed

Influenza Immunity in Children

Influenza

United States
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Quadrivalent Influenza Vaccine Among Adults

Influenza

United States
PT Bio Farma

Completed

Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population

Safety Issues

Indonesia
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

France, Belgium, Germany, Italy, Netherlands, Poland

3

Subscribe